POSTER PRESENTATION Open Access Quality compliance in the development of cell- based medicines in non-pharma environments


Academic institutions and transfusion centres are posi-tioned to lead the development of novel cell-based ther-apeutics up to early-stage clinical trials (and further seeking marketing authorisation) or, alternatively, its use under the hospital exemption clause [1,2]. Existing structures, including blood and tissue bank facilities, translational medical programs and skilled personnel experienced in cell culture technologies and transplanta-tion, equips these non-commercial entities to translate research-grade cell materials into safe and commercially viable products suitable for human use. However, devel-opers must negotiate the complex regulatory and quality requirements involving the compulsory compliance of Good Scientific Practice (GxP) regulations in the devel-opment of advanced therapy medicinal product

Similar works

Full text

oai:CiteSeerX.psu: time updated on 10/30/2017

This paper was published in CiteSeerX.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.